CANCER RESEARCH UK AND NOVALGEN DOSE THE FIRST PATIENT IN THE PHASE 1 TRIAL OF T-CELL ENGAGER NVG-222
Cancer Research UK's Centre for Drug Development (CDD) and NovalGen today announce that the first patient has been dosed in a Phase 1 clinical trial evaluating NVG‑2...





